StockData

Baird Medical Investment vs Profound Medical

BDMD and PROF side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BDMD and PROF compare

Profound Medical grew revenue faster over the last twelve months (65.3% versus −39.2% for Baird Medical Investment).

Baird Medical Investment keeps more of each dollar of sales as profit, with a net margin of −121% compared with −138% at Profound Medical.

Profound Medical scores higher on the StockData Score (5 against 2 for Baird Medical Investment), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBDMDPROF
Size and price
Share price$0.104$7.85
Change, 1 year−91.7%31.1%
Change, 5 years–−35.6%
Beta (5Y)−0.041.03
Employees146162
StockData Score
Total score25 (better)
Valuation score00
Growth score03 (better)
Performance score00
Health score22
Dividend score00
Growth
Revenue growth (TTM)−39.2%65.3% (better)
Revenue growth, 5Y average–17.1%
Net income growth (TTM)−319%–
EPS growth (TTM)−272%–
EPS growth, 5Y average–2.4%
Profitability
Gross margin83.8% (better)73.9%
Operating margin−114% (better)−145%
Net margin−121% (better)−138%
FCF margin−6.2%–
Return on equity−77.5% (better)−87.0%
Return on invested capital−48.2% (better)−213%
Financial health
Debt / equity0.220.11 (better)
Interest coverage−72.3× (better)−105.8×
Current ratio1.294.54 (better)
Piotroski F-score13 (better)
Ownership
Held by institutions–45.2%
Held by insiders62.0%1.6%
Short interest, % of float–4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.